BioCentury: Elicio’s cancer vaccine boosts CAR Ts for solid tumors

CAR T cell therapies have been approved to treat hematologic cancers, but have shown little success in treating solid tumors.

Elicio Therapeutics (Cambridge, Mass.), which launched in March, exclusively licensed the platform, Amphiphile, from co-founder Darrell Irvine at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology ┬╗FULL STORY